A federal review board voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is non-binding. The FDA has given no clear statement on whether it will move in step with the panel. The move came after weeks of stakeholder sessions. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could reshape how the agency handles a part of the wellness market that is surging ahead. Patient groups are waiting to see if the agency takes up the plan. A representative for the agency offered no clear schedule for a follow-up. Industry voices argue the change would expand access to products that users favor. Opponents warn that looser rules could open the door to misuse across a wide-open market. The panel vote only lays the groundwork for change, and the ultimate call rests with the federal agency.